Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.8000
- TODAY'S CHANGE (%)-0.0300 (-0.7833%)
- Bid / Lots3.7900/ 1
- Ask / Lots3.8000/ 2
- Open / Previous Close3.9200 / 3.8300
- Day Range
- 52 Week Range
- Volume161,384
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 3419 | 3.93 |
| 09:36 ET | 1606 | 4 |
| 09:38 ET | 6716 | 3.9801 |
| 09:39 ET | 1085 | 3.98 |
| 09:41 ET | 3000 | 3.96 |
| 09:43 ET | 772 | 3.95 |
| 09:45 ET | 421 | 3.9142 |
| 09:48 ET | 839 | 3.92 |
| 09:50 ET | 14785 | 3.93 |
| 09:52 ET | 100 | 3.95 |
| 09:54 ET | 400 | 3.97 |
| 09:56 ET | 1000 | 3.98 |
| 09:57 ET | 100 | 3.97 |
| 09:59 ET | 200 | 3.95 |
| 10:01 ET | 147 | 3.9399 |
| 10:03 ET | 200 | 3.9519 |
| 10:06 ET | 200 | 3.935 |
| 10:08 ET | 400 | 3.94 |
| 10:10 ET | 3200 | 3.92 |
| 10:12 ET | 2677 | 3.93 |
| 10:14 ET | 520 | 3.93 |
| 10:17 ET | 200 | 3.9 |
| 10:19 ET | 980 | 3.88 |
| 10:21 ET | 1000 | 3.88 |
| 10:24 ET | 100 | 3.875 |
| 10:26 ET | 140 | 3.875 |
| 10:28 ET | 300 | 3.87 |
| 10:30 ET | 596 | 3.855 |
| 10:33 ET | 100 | 3.84 |
| 10:35 ET | 238 | 3.846 |
| 10:37 ET | 7697 | 3.87 |
| 10:42 ET | 1435 | 3.87 |
| 10:44 ET | 873 | 3.9 |
| 10:46 ET | 100 | 3.91 |
| 10:50 ET | 200 | 3.91 |
| 10:51 ET | 400 | 3.915 |
| 10:53 ET | 872 | 3.92 |
| 10:55 ET | 100 | 3.9 |
| 10:57 ET | 100 | 3.9 |
| 11:00 ET | 100 | 3.9 |
| 11:04 ET | 300 | 3.9 |
| 11:06 ET | 870 | 3.9 |
| 11:08 ET | 200 | 3.905 |
| 11:09 ET | 705 | 3.915 |
| 11:13 ET | 2035 | 3.9 |
| 11:18 ET | 100 | 3.905 |
| 11:20 ET | 100 | 3.87 |
| 11:22 ET | 200 | 3.87 |
| 11:24 ET | 100 | 3.87 |
| 11:26 ET | 386 | 3.87 |
| 11:27 ET | 100 | 3.86 |
| 11:29 ET | 2312 | 3.88 |
| 11:36 ET | 200 | 3.875 |
| 11:38 ET | 11079 | 3.87 |
| 11:40 ET | 100 | 3.865 |
| 11:42 ET | 100 | 3.86 |
| 11:44 ET | 1428 | 3.87 |
| 11:49 ET | 200 | 3.87 |
| 11:51 ET | 100 | 3.875 |
| 11:54 ET | 5492 | 3.8749 |
| 11:56 ET | 15478 | 3.86 |
| 11:58 ET | 1434 | 3.87 |
| 12:02 ET | 1810 | 3.88 |
| 12:05 ET | 283 | 3.88 |
| 12:07 ET | 100 | 3.88 |
| 12:09 ET | 300 | 3.87 |
| 12:12 ET | 100 | 3.86 |
| 12:14 ET | 875 | 3.86 |
| 12:16 ET | 300 | 3.86 |
| 12:18 ET | 300 | 3.8545 |
| 12:20 ET | 2812 | 3.87 |
| 12:23 ET | 200 | 3.865 |
| 12:25 ET | 2127 | 3.87 |
| 12:30 ET | 100 | 3.875 |
| 12:32 ET | 200 | 3.87 |
| 12:36 ET | 100 | 3.865 |
| 12:38 ET | 200 | 3.865 |
| 12:39 ET | 200 | 3.865 |
| 12:41 ET | 736 | 3.88 |
| 12:48 ET | 1337 | 3.89 |
| 12:50 ET | 100 | 3.875 |
| 12:52 ET | 2732 | 3.88 |
| 12:57 ET | 207 | 3.88 |
| 12:59 ET | 300 | 3.88 |
| 01:03 ET | 500 | 3.87 |
| 01:10 ET | 100 | 3.85 |
| 01:12 ET | 1805 | 3.84 |
| 01:14 ET | 3100 | 3.845 |
| 01:15 ET | 2600 | 3.805 |
| 01:17 ET | 312 | 3.81 |
| 01:19 ET | 4591 | 3.79 |
| 01:21 ET | 450 | 3.785 |
| 01:24 ET | 200 | 3.79 |
| 01:26 ET | 300 | 3.78 |
| 01:32 ET | 2090 | 3.79 |
| 01:35 ET | 100 | 3.79 |
| 01:39 ET | 200 | 3.78 |
| 01:44 ET | 500 | 3.79 |
| 01:46 ET | 350 | 3.785 |
| 01:50 ET | 321 | 3.775 |
| 01:51 ET | 530 | 3.77 |
| 01:55 ET | 858 | 3.79 |
| 02:00 ET | 100 | 3.8 |
Yesterday
May 2, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform, from 4:30PM ET on Thursday May 02, 2024 by Dow Jones
4:30PM ET on Thursday May 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 201.2M | -0.8x | --- |
Acumen Pharmaceuticals Inc | 201.9M | -3.4x | --- |
INmune Bio Inc | 196.2M | -6.2x | --- |
Prelude Therapeutics Inc | 208.7M | -2.1x | --- |
Zura Bio Ltd | 208.8M | -1.1x | --- |
Elevation Oncology Inc | 193.4M | -3.4x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $201.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.47 |
EPS | $-4.97 |
Book Value | $5.06 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
